ZN-d5-001
08 Jun 2021
Trial Summary
This is a Phase 1 dose escalation, open label, multicenter study, evaluating the safety, tolerability, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of ZN-d5 in subjects with Non-Hodgkin Lymphoma (NHL) and subjects with Acute Myeloid Leukemia (AML).
Acronym:
ZN-d5-001
ACTRN/NCT /ethics:
NCT04500587
Scientific title:
Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia
Sponsor / Cooperative group:
K-Group Alpha, Inc.
Trial & Patient Characteristics
| Cancer Type | Non-Hodgkin Lymphoma; Acute Myeloid Leukemia |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2020-10-13 |
| Anticipated End Date | 2023-05-01 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Akash Kalro |
| Recruitment Status | Recruiting |